Forte Biosciences (FBRX) Cash & Current Investments (2016 - 2026)

Forte Biosciences (FBRX) has reported Cash & Current Investments for 11 consecutive years, with $58.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 26.92% year-over-year to $58.2 million; the TTM figure through Mar 2026 stood at $58.2 million (up 26.92% YoY), while the FY2025 annual figure was $77.0 million, up 31.85% from the prior year.
• Cash & Current Investments slipped to $58.2 million in Q1 2026 per FBRX's latest filing, from $77.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $106.1 million in Q2 2025 and bottomed at $16.4 million in Q3 2024.
• Historically, Cash & Current Investments has averaged $48.4 million across 5 years, with a median of $41.1 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Current Investments sank 64.49% — and 2025, when it soared 469.51%.
• Forte Biosciences' Cash & Current Investments stood at $41.1 million in 2022, then slipped by 9.67% to $37.1 million in 2023, then surged by 57.21% to $58.4 million in 2024, then soared by 31.85% to $77.0 million in 2025, then retreated by 24.37% to $58.2 million in 2026.
• Business Quant data shows FBRX's Cash & Current Investments at $58.2 million in Q1 2026, $77.0 million in Q4 2025, and $93.4 million in Q3 2025.